Search Within

Matthew J Matasar

  1. "Center for Hematologic Malignancies"
  2. "Population Sciences Research Program"
  3. "Ariela Noy"
  4. "2021"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (6)
Groups
  1. Center for Hematologic Malignancies (14)
  2. Department of Medicine (14)
  3. Hematologic Malignancies, Division of (14)
  4. Lymphoma (14)
  5. Population Sciences Research Program (14)
  6. Survivorship Research (14)

More Groups

People
  1. Ariela Noy (14)
  2. David Straus (14)
  3. Steven Horwitz (14)
  4. Alison Moskowitz (12)
  5. Andrew Zelenetz (12)
  6. Anita Kumar (12)

More People

Years
  1. 2021 (14)
Publications
  1. Blood (6)
  2. Journal of Clinical Oncology (3)
  3. Hematological Oncology (2)
  4. American Journal of Hematology (1)
  5. Blood Advances (1)
  6. Blood Cancer Journal (1)
Publishers
  1. American Society of Hematology (7)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (2)
  4. John Wiley & Sons, Inc. (1)
  5. Nature Publishing Group (1)

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Complete remission with devimistat (CPI-613) in refractory Burkitt lymphoma
    Meeting Abstract

    Nikolaenko, L.; Pardee, T.; Steiner, R.; Abramson, J. S.; Horwitz, S. M.; Matasar, M. J.; Owens, C.; Rodriguez-Rivera, I.; Straus, D. J.; Luther, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
    Journal Article

    Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Preliminary activity of devimistat (CPI 613) in patients with relapsed or refractory Burkitt lymphoma/leukemia
    Meeting Abstract

    Nikolaenko, L.; Pardee, T. S.; Steiner, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez-Rivera, I.; Straus, D.; Luther, S.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save